Unlock instant, AI-driven research and patent intelligence for your innovation.

Biguanide and probucol composition medicament for treating nonalcoholic fatty liver disease

A technique of non-alcoholic, probucol used in the field of pharmacy to achieve the effect of good curative effect and good therapeutic effect

Inactive Publication Date: 2013-04-17
INNER MONGOLIA MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no effective treatment for NAFLD, and various comprehensive measures such as diet control, exercise, blood fat reduction, and low insulin resistance are generally adopted.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biguanide and probucol composition medicament for treating nonalcoholic fatty liver disease
  • Biguanide and probucol composition medicament for treating nonalcoholic fatty liver disease
  • Biguanide and probucol composition medicament for treating nonalcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0017] Below, examples are given, as a more detailed description of the present invention, biguanide drugs are represented by metformin, phenformin and buformin, and the effect of compound combination drugs on non-alcoholic fatty liver is studied, but the scope of the present invention It is not limited to this.

[0018] Preparation part

[0019] 1. Preparation of biguanides and probucol compound tablets with different content ratios

[0020] Table 1 embodiment 1~6 probucol metformin tablet prescription composition (1000)

[0021]

[0022]

[0023] Preparation Process:

[0024] (1) The raw materials of the prescription amount are weighed and passed through a 100-mesh sieve respectively, and then mixed by the method of equal increments for subsequent use;

[0025] (2) According to the above table 1, weigh the other excipients of the prescription amount and mix them for later use;

[0026] (3) Add an appropriate amount of binder to make soft materials, granulate with ...

Embodiment

[0109] Fifty healthy Wistar rats (provided by Hohhot Experimental Animal Center), half male and half male, weighing (200±10) g, were used for the pharmacodynamic experiment. The animals are randomly divided into 5 groups (10 rats in each group), control group; model group; probucol group (100mg / kg / d, Shandong Qilu Pharmaceutical Co. Methylcellulose sodium solution preparation.); Metformin group (150mg / kg, adult dose 1.5g·d -1 converted into sodium carboxymethylcellulose and prepared into a solution with a concentration of 15 mg / mL); probucol + metformin group. The dosage of each group is shown in Table 1. Rats were given intragastric administration of fat emulsion, and on the basis of hyperlipidemia, they continued to be given a high-fat diet (containing 260g of casein, 150g of cornstarch, 90g of sucrose, 400g of butter, 50g of cellulose, 40g of minerals, and vitamins per kilogram). 10g) Replicate the NAFLD model. Except for the control group, each group was given fat emuls...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition. The medicinal composition comprises a biguanide hypoglycemic medicine, a probucol lipid-lowering medicine and a medicinal vector, wherein the biguanide hypoglycemic medicine is selectively in a pharmaceutically acceptable salt form. The medicinal composition is suitable for treating nonalcoholic fatty liver disease.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing biguanide hypoglycemic drugs, probucol lipid-lowering drugs and pharmaceutically acceptable carriers. The pharmaceutical composition is used for preventing and treating nonalcoholic fatty liver, and the invention belongs to the field of pharmacy. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is currently considered to be a clinical syndrome characterized by hepatic steatosis and fat accumulation caused by alcohol and other definite liver-damaging factors. NAFLD is closely related to insulin resistance-related obesity and type 2 diabetes. It is the manifestation of metabolic syndrome in the liver. Dyslipidemia is one of the important factors for the formation of fatty liver. The mechanism of hyperlipidemia-induced fatty liver may be related to the "secondary The first hit is mainly insulin resistance, which causes benign liver cell lipid deposition, and the secon...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/10A61K31/155A61P1/16A61P3/04A61P3/06A61P3/10
Inventor 李刚郭敏李长胜马慧尹若熙徐俊梅
Owner INNER MONGOLIA MEDICAL UNIV